Mogrify Limited, a UK company aiming to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies, and the MRC Laboratory of Molecular Biology (LMB), a research laboratory dedicated to understanding important biological processes at the molecular level, has announced an exploratory research collaboration.   The project aims to develop novel protein expression systems by leveraging recent advances in direct cell reprogramming to help improve the ...